NEW YORK, Dec. 8, 2016 /PRNewswire/ -- This report analyzes the worldwide markets for Prophylactic Human Vaccines in US$ Million by the following Product Segments: Pediatric Prophylactic Vaccines, and Adult Prophylactic Vaccines. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 63 companies including many key and niche players such as -
ALK Abelló A/S
Altimmune, Inc.
Bavarian Nordic A/S
BiondVax Pharmaceuticals Ltd.
Bharat Biotech International Limited
Read the full report: http://www.reportlinker.com/p04089493-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Prophylactic Vaccines..............I-3
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW & OUTLOOK..............II-1 Human Vaccines: A Prelude..............II-1 Human Vaccines Market - A Snapshot II-1 Market Dynamics.............. II-2 Growth Drivers in a Capsule..............II-3 Developed World: The Key Markets II-4 Emerging Markets: The Future Growth Area II-4 Vaccine Pricing: The Developed - Developing Divide II-5
2. MARKET TRENDS & ISSUES..............II-6 Prophylactic Pediatric Vaccines - A Mature Market II-6 Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers..............II-6 Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines..............II-7 Novel Vaccines against Emerging Infectious Diseases II-7 Ongoing Developments for a Vaccine against Zika Virus II-7 Sanofi's Dengue Vaccine First-to-Market II-8 Pipeline & Marketed Dengue Vaccine: 2016 II-9 Computational Tools Come to Aid in Development of Ebola Vaccines II-10 Vaccine for AIDS.............. II-10 Ongoing Research for HIV Vaccine & Commercial Pipeline II-10 List of Clinical Trial (Phase II) AIDS Vaccines: 2015 II-11 Staggering Global Statistics of AIDS - Opportunity Indicator II-12 Table 1: HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart) II-12
Table 2: Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart).............. II-13
Table 3: Worldwide AIDS related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart) II-14
Table 4: HIV-Positive Individuals, by Gender (2014): Percentage Breakdown of Women and Men Tested HIV-Positive in all WHO Regions (includes corresponding Graph/Chart) II-14 Vaccination-Autism Link and Other Safety Concerns Thwarted II-15 Threat of Pandemic Rejuvenates Vaccine Market II-15 Influenza Vaccines on a Growing Spree II-15 Influenza Vaccines on the Current Market: 2016 II-16 H1N1 Vaccines Hit the Market in August 2009 II-16 H1N1 Influenza Vaccines and Manufacturers II-17 Influenza Market Faces Several Challenges II-18 Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market II-19 Unmet Demand for TB Vaccine..............II-21 Key TB Vaccine Candidates in the Pipeline: 2016 II-22 Need for a Human Vaccine for Leishmaniasis II-22 Economic Factors Hamper Optimal Vaccine Development and Delivery II-22 Increasing Need for Vaccine Promotion in the Developing Regions II-22 Changing Vaccine Needs..............II-23 Religious Concerns over Immunizing Young Girls against Human Papillomavirus.............. II-23 Changing Travel Patterns Increase Demand for Hepatitis B Vaccine II-23 DNA Vaccines: Engineering Growth II-23 Noninjectable Vaccines: Gain without Pain II-25 Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines.............. II-25 Conjugate Vaccines: A Technological Innovation II-26 Hib Vaccines on the Market: 2016 II-26 Growing Pricing Pressure - A Major Market Deterrent II-27 Safety Issues Come to the Fore II-27 BioWarfare: Threat Perception and Preparedness II-27 Overview of Potential Bio-Terrorist Agents II-28 Smallpox (Variola Major)..............II-28 Anthrax (Bacillus Anthracis)..............II-28 Plague (Yersinia Pestis)..............II-29 Botulism (Clostridium Botulinum) II-29 Tularemia (Francisella Tularensis) II-29 Tackling Cold Chain Issues..............II-29 Trade Statistics.............. II-30 Table 5: Global Exports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart).............. II-30
Table 6: Global Imports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart).............. II-31
3. COMPETITIVE LANDSCAPE..............II-32 Competitive Scenario..............II-32 Leading Players.............. II-32 Table 7: Leading Players in the Global Human Vaccines Market (2015): Annual Sales in US$ Million for GlaxoSmithKline, Merck, Pfizer and Sanofi (includes corresponding Graph/Chart) II-33
Table 8: Top Five Human Vaccines Worldwide by Sales Value: 2015 (In US$ Million) (includes corresponding Graph/Chart) II-34 Pfizer Scores Big with Prevnar II-34 Trumenba Shows Promise in Phase III Clinical Trials II-35 GSK Takes Big Leap into the Meningococcal Vaccine Market II-35 Acquired Products Strengthen GSK's Vaccines Sales II-36 The Potential for MenABCWY Vaccine II-36 Table 9: US Meningococcal Disease Incidence by Serogroup Distribution (1990 & 2013): Percentage Breakdown of Disease Incidence for Serotypes B, C, Y and Others (includes corresponding Graph/Chart)..............II-37 Sanofi Works on Production Issues to Boost Sales II-37 New Vaccines to Enhance Prospects for Sanofi II-38 Sanofi's Human Vaccine R&D Pipeline II-38 Weaker Sales Drive Merck and Sanofi's European JV Split II-39 Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market.............. II-39
4. PRODUCT OVERVIEW.............. II-40 Introduction to the Concept of Immunity II-40 Role of Vaccines in Strengthening the Immune System II-40 Vaccines and Immunotherapy..............II-41 Historical Overview of Vaccines..............II-41 How it Began.............. II-41 So Far So Good.............. II-42 Successful Vaccine Introductions in the Past II-43 Contribution of Animal Research to Vaccine Production II-43 Types of Vaccines.............. II-44 Live, Attenuated Vaccines..............II-44 Combination Vaccines..............II-45 Killed or Inactivated Vaccines..............II-45 DNA & Recombinant DNA Vaccines..............II-46 Toxoids.............. II-47 Cellular Fractions.............. II-47 Conjugate Vaccines.............. II-47 Subunit Vaccines.............. II-47 Passive Immunization..............II-48 Prophylactic Vaccines..............II-48 Prevention Better than Cure..............II-48 Prophylactic Pediatric Vaccines II-48 Vaccination over the Years..............II-48 BCG Vaccine.............. II-49 Growth Boosting Factors for TB Vaccines II-49 Demand Restraining Factors for TB Vaccines II-49 Major Issues to be addressed in the TB Vaccine Market II-50 Hemophilus Influenza Type B Vaccine II-50 Diphtheria/Tetanus/Pertussis Vaccines II-50 Hepatitis A Vaccine..............II-50 Hepatitis B Vaccine..............II-50 Hepatitis B Epidemiology..............II-51 Measles/Mumps/Rubella Vaccines..............II-51 Rotavirus Vaccines.............. II-51 Polio Vaccines.............. II-51 Varicella Vaccine..............II-52 Combination Vaccines..............II-52 Prophylactic Adult Vaccines..............II-53 Hepatitis A Vaccine..............II-53 Hepatitis B Vaccines..............II-54 Key Issues Affecting the Adult Hepatitis Vaccines Market II-55 Cholera Vaccine.............. II-55 Japanese Encephalitis Vaccines..............II-55 Influenza Vaccines.............. II-56 Influenza A Virus.............. II-56 Influenza A (H1N1) Virus..............II-56 Vaccine Virus Selection for the 2015-2016 Influenza Season II-57 WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2015-2016 II-57 WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2015-2016 II-57 Lyme Disease Vaccine..............II-58 Pneumococcal Disease Vaccines II-58 Meningococcal Vaccines..............II-59 Rabies Vaccines.............. II-59 Typhoid Vaccine.............. II-60 Yellow Fever Vaccine..............II-60 Mechanisms for Vaccine Delivery..............II-60 Edible Vaccines.............. II-60 Oral Vaccines.............. II-62 Tablet Based Vaccines..............II-62 Mucosal Delivery.............. II-62 Transdermal Patch Delivery..............II-62 Storage Problems.............. II-62 Perfluorocarbons as Alternative to Overcome Storage Problems II-63 Costs.............. II-63 Standards for Vaccine Safety and Quality II-63
5. CLINICAL TRIALS IN THE VACCINES MARKET II-64 Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine.............. II-64 Takeda Begins Phase2b Trial for World's First Norovirus Vaccine II-64 Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine.............. II-64 Investigational Vaccine for P.vivax Malaria Enters Human Trials II-64 Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C.difficile..............II-64 Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine..............II-64 Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine II-65 Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies II-65 Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial II-65
6. PRODUCT LAUNCHES/APPROVALS..............II-66 FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok..............II-66 Sanofi's Dengue Vaccine Approved in Costa Rica II-66 GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line II-66 FDA Approves Seqirus' FLUCELVAX QUADRIVALENT™ Influenza Vaccine II-66 China Launches HFMD Vaccine..............II-66 Bharat Biotech Introduces ZIKAVAC® Vaccine for Zika Infection II-66 Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection.............. II-66 WHO Accepts Merck's Investigational Ebola Vaccine Application for Review.............. II-67 Sanofi's Dengvaxia® Receives Marketing Authorization in Mexico II-67 SK Chemicals Launches Influenza Vaccine SKYCellflu II-67 Sanofi Pasteur Ships First Doses of Fluzone® for the US Market II-67 Bharat Biotech Launches Made-in-India ROTAVAC® Vaccine II-67 FDA Approves Sanofi's sBLA for Fluzone Vaccine II-67 FDA Approves Merck's HPV Vaccine GARDASIL®9 II-67 Sanofi Pasteur Launches Shan5™ Vaccine Developed by its Affiliate Shantha..............II-68 US FDA Approves First Meningococcal Disease Vaccine Trumenba II-68
7. RECENT INDUSTRY ACTIVITY..............II-69 WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar 13..............II-69 Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility II-69 Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government.............. II-69 Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines..............II-69 WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue.............. II-69 Kaketsuken to Sell Vaccines Business to Astellas II-69 Sanofi and Merck End Joint Venture on Vaccines II-70 GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine.............. II-70 Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA.............. II-70 Bavarian Nordic Enters into License Agreement with Janssen II-70 CSL Rebrands Influenza Vaccines Business as Seqirus II-70 MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D..............II-70 GlaxoSmithKline Acquires Novartis' Vaccines Business II-71 Vaxin Changes Name to Altimmune..............II-71 Takeda Expands Commercialization Agreement with Nanotherapeutics II-71 MedImmune Enters Into License Agreement with Inovio Pharmaceuticals.............. II-71 CSL Completes Acquisition of Novartis' Influenza Vaccines Business.............. II-71 Pfizer to Acquire Meningitis Vaccines from GSK II-71 Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License..............II-71 Takeda Transfers HPV Vaccine License Agreement to Kaketsuken II-71 GlaxoSmithKline Acquires GlycoVaxyn II-72 Pfizer Acquires Redvax GmbH..............II-72 Pfizer Acquires Baxter's Vaccines and Portion of Manufacturing Facility.............. II-72
8. FOCUS ON SELECT PLAYERS..............II-73 ALK - Abelló A/S (Denmark)..............II-73 Altimmune, Inc. (US)..............II-73 Bavarian Nordic A/S (Denmark)..............II-73 BiondVax Pharmaceuticals Ltd. (Israel) II-74 Bharat Biotech International Limited (India) II-74 GlaxoSmithKline Plc. (UK)..............II-74 Hualan Biological Engineering Inc. (China) II-75 Janssen Pharmaceuticals, Inc. (US) II-75 MedImmune (US).............. II-76 Merck & Co., Inc. (US)..............II-76 Pfizer Inc. (US).............. II-76 Sanofi Pasteur SA (France)..............II-77 Serum Institute of India Pvt. Ltd. (India) II-78 Shanghai BravoBio Co., Ltd. (China) II-78 Seqirus (UK).............. II-78 SK Chemicals Co., Ltd. (Korea) II-79 Takeda Pharmaceutical Company Limited (Japan) II-79 Zydus Cadila (India)..............II-79
9. GLOBAL MARKET PERSPECTIVE..............II-81 Table 10: World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines Prophylactic by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-81
Table 11: World Historic Review for Prophylactic Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-82
Table 12: World 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-83
Table 13: World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-84
Table 14: World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-85
Table 15: World 14-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-86
Table 16: World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-87
Table 17: World Historic Review for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............II-88
Table 18: World 14-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-89
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 Outlook.............. III-1 Key Growth Drivers..............III-1 Select Market Constraints..............III-1 Major Trends in the US Vaccines Development III-1 Increasing Consolidation Activity among Companies III-1 Combination Vaccines and New Delivery Models Gaining Traction III-2 Protests against Vaccination Make Companies More Cautious III-2 Technological Challenges in the Development of RSV Vaccines III-2 Pediatric Vaccines Market..............III-3 Improved Pricing Scenario for Pediatric Vaccines III-3 Market Focus Shifting from Pediatric Vaccines III-3 Growth Drivers for US Pediatric Vaccines Market III-3 Demand Restraining Factors for US Pediatric Vaccines Market III-4 Opportunity Indicators..............III-4 Table 19: Number of Reported Cases for Vaccine-Preventable Diseases in American Regions: 2009-2013 III-4
Table 20: Routine Immunization Coverage in the US (2011-2013): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).............. III-5 The US Influenza Vaccine Market III-5 'Swine Flu' Strain Returns in the 2013-14 Season III-5 Table 21: CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016 III-6 Table 22: CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016..............III-7 A Background on the Need for Flu Vaccines III-7 Need for Immunization Schedule for Adults III-8 Vaccines and Intended User Group III-8 Adult Population: To Drive Future Growth of Pertussis Vaccines Market.............. III-9 Table 23: Pertussis Cases (In Thousands) for Years 2000 through 2014 (includes corresponding Graph/Chart) III-9 Vaccine Pricing in the US..............III-9 Regulatory Environment..............III-10 Review Process Make Vaccines Safer III-10 Imports-Exports Scenario..............III-10 Table 24: US Exports of Human Vaccines by Country (2014 & 2015) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart) III-11
Table 25: US Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart) III-12 Clinical Trials.............. III-13 Product Launches..............III-14 Strategic Corporate Developments III-14 Select Players.............. III-16 B.Market Analytics..............III-20 Table 26: US Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-20
Table 27: US Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-21
Table 28: US 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-22
2. CANADA.............. III-23 A.Market Analysis.............. III-23 Outlook.............. III-23 Opposition to CMA's Mandatory Vaccination Program III-23 2009 H1N1 Pandemic Boosts Vaccines Sales III-23 Trade Statistics..............III-24 Table 29: Canadian Exports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart) III-24
Table 30: Canadian Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart).............. III-25 B.Market Analytics..............III-26 Table 31: Canadian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-26
Table 32: Canadian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-27
Table 33: Canadian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-28
3. JAPAN.............. III-29 A.Market Analysis.............. III-29 Outlook.............. III-29 Controversy, Confusion and Hasty Actions Marr HPV Vaccination Market..............III-29 Strategic Corporate Developments III-29 Key Japan-based Player - Takeda Pharmaceutical Company Limited III-30 B.Market Analytics..............III-31 Table 34: Japanese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-31
Table 35: Japanese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-32
Table 36: Japanese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-33
4. EUROPE.............. III-34 A.Market Analysis.............. III-34 Outlook.............. III-34 Vaccine Pricing in Europe..............III-34 Major Drawbacks.............. III-34 Regulatory Mechanism for Vaccines in Europe III-34 An Insight into European Influenza Vaccination Scenario III-35 H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation..............III-35 Cell-based Vaccine Production Remains Nascent, Egg-based widely used.............. III-35 EU Welcomes Quadrivalent LAIVs III-35 Major Influenza Vaccines Available in European Union Member Countries..............III-36 Major H1N1 Flu Vaccines Available in Select East European Markets.............. III-36 B.Market Analytics..............III-37 Table 37: European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-37
Table 38: European Historic Review for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-38
Table 39: European 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-39
Table 40: European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-40
Table 41: European Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-41
Table 42: European 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-42
4a. FRANCE.............. III-43 A.Market Analysis.............. III-43 Outlook.............. III-43 Clinical Trial.............. III-43 Product Launches..............III-43 Strategic Corporate Developments III-44 Key Players.............. III-44 B.Market Analytics..............III-46 Table 43: French Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-46
Table 44: French Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-47
Table 45: French 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-48
4b. GERMANY.............. III-49 Market Analysis.............. III-49 Table 46: German Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-49
Table 47: German Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-50
Table 48: German 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-51
4c. ITALY.............. III-52 Market Analysis.............. III-52 Table 49: Italian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-52
Table 50: Italian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-53
Table 51: Italian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-54
4d. THE UNITED KINGDOM..............III-55 A.Market Analysis.............. III-55 Outlook.............. III-55 Product Launch.............. III-55 Strategic Corporate Developments III-55 Select Players.............. III-56 B.Market Analytics..............III-57 Table 52: UK Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-57
Table 53: UK Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-58
Table 54: UK 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-59
4e. SPAIN.............. III-60 Market Analysis.............. III-60 Table 55: Spanish Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-60
Table 56: Spanish Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-61
Table 57: Spanish 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-62
4f. RUSSIA.............. III-63 Market Analysis.............. III-63 Table 58: Russian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-63
Table 59: Russian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-64
Table 60: Russian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-65
4g. REST OF EUROPE.............. III-66 A.Market Analysis.............. III-66 Outlook.............. III-66 Clinical Trial.............. III-66 Strategic Corporate Developments III-66 Select Players.............. III-67 B.Market Analytics..............III-68 Table 61: Rest of Europe Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-68
Table 62: Rest of Europe Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-69
Table 63: Rest of Europe 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. III-70
5. ASIA-PACIFIC.............. III-71 A.Market Analysis.............. III-71 Outlook.............. III-71 Asian Vaccine Industry..............III-71 Challenges.............. III-71 2014-15: Deadliest Swine Flu Season in India Since 2009 III-72 Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets..............III-72 B.Market Analytics..............III-73 Table 64: Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-73
Table 65: Asia-Pacific Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-74
Table 66: Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............III-75
Table 67: Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-76
Table 68: Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-77
Table 69: Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-78
5a. CHINA.............. III-79 A.Market Analysis.............. III-79 Outlook.............. III-79 Large Population Offers High Potential III-79 Growth Drivers.............. III-79 China - A Lucrative yet Difficult to Permeate Market III-80 Product Launch.............. III-80 Strategic Corporate Development III-81 Key Players.............. III-81 B.Market Analytics..............III-82 Table 70: Chinese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-82
Table 71: Chinese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-83
Table 72: Chinese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-84
5b. INDIA.............. III-85 A.Market Analysis.............. III-85 Current & Future Analysis..............III-85 Market Overview.............. III-85 Hepatitis B Vaccine in India III-85 Combination Vaccines..............III-86 Indian Vaccine Market - Select Combination Vaccines Available in the Country..............III-87 The Patent Act (Third Amendment), 2005 III-87 Product Launches..............III-87 Strategic Corporate Development III-88 Select Players.............. III-88 B.Market Analytics..............III-91 Table 73: Indian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-91
Table 74: Indian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-92
Table 75: Indian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-93
5c. REST OF ASIA-PACIFIC..............III-94 A.Market Analysis.............. III-94 Outlook.............. III-94 Malaysia - Stricken by Vaccine Shortage III-94 Product Launches..............III-94 Strategic Corporate Developments III-95 Key Korea-based Player - SK Chemicals Co., Ltd. III-95 B.Market Analytics..............III-96 Table 76: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-96
Table 77: Rest of Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-97
Table 78: Rest of Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. III-98
6. LATIN AMERICA.............. III-99 Market Analysis.............. III-99 Table 79: Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart).............. III-99
Table 80: Latin American Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-100
Table 81: Latin American 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)..............III-101
Table 82: Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-102
Table 83: Latin American Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-103
Table 84: Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. III-104
6a. BRAZIL.............. III-105 Market Analysis.............. III-105 Table 85: Brazilian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)..............III-105
Table 86: Brazilian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-106
Table 87: Brazilian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-107
6b. REST OF LATIN AMERICA..............III-108 A.Market Analysis.............. III-108 Outlook.............. III-108 Product Launches..............III-108 B.Market Analytics..............III-109 Table 88: Rest of Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-109
Table 89: Rest of Latin American Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-110
Table 90: Rest of Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. III-111
7. REST OF WORLD.............. III-112 A.Market Analysis.............. III-112 Outlook.............. III-112 Nigeria: A Severely Underserved Market III-112 Table 91: Deaths in Nigerian Children Under Five Years by Cause (2015): Percentage Breakdown of Number of Deaths due to Diarrhoea, Malaria, Measles, Neonatal, Pneumonia, and Others (includes corresponding Graph/Chart) III-112 BiondVax Pharmaceuticals Ltd. - A Key Israel-based Player III-113 B.Market Analytics..............III-113 Table 92: Rest of World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-113
Table 93: Rest of World Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-114
Table 94: Rest of World 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-115
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 63 (including Divisions/Subsidiaries - 72)
The United States (22) Canada (1) Japan (5) Europe (14) - France (3) - Germany (2) - The United Kingdom (2) - Spain (1) - Rest of Europe (6) Asia-Pacific (Excluding Japan) (28) Latin America (1) Middle East (1)
Read the full report: http://www.reportlinker.com/p04089493-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article